| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study
|
Brown, Jennifer R.
|
|
|
9 |
8 |
p. 1918-1926
|
artikel
|
| 2 |
A model of zymogen factor XII: insights into protease activation
|
Shamanaev, Aleksandr
|
|
|
9 |
8 |
p. 1940-1951
|
artikel
|
| 3 |
Audit of B-cell cancer genes
|
Coyle, Krysta M.
|
|
|
9 |
8 |
p. 2019-2031
|
artikel
|
| 4 |
C3 as a predictive and prognostic biomarker in adult hemophagocytic lymphohistiocytosis: a large cohort study in China
|
Shu, Xuemei
|
|
|
9 |
8 |
p. 1836-1846
|
artikel
|
| 5 |
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
|
Pierson, Sheila K.
|
|
|
9 |
8 |
p. 1952-1965
|
artikel
|
| 6 |
Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alfa
|
Kalmer, Milena
|
|
|
9 |
8 |
p. 1873-1887
|
artikel
|
| 7 |
Distress and symptom burden in patients with monoclonal gammopathy of undetermined significance and smoldering myeloma
|
O’Donnell, Elizabeth K.
|
|
|
9 |
8 |
p. 1984-1987
|
artikel
|
| 8 |
Efficacy and safety of dapsone in adult primary immune thrombocytopenia
|
Larue, Marion
|
|
|
9 |
8 |
p. 1976-1983
|
artikel
|
| 9 |
Fedratinib in 2025 and beyond: indications and future applications
|
Coltoff, Alexander
|
|
|
9 |
8 |
p. 1907-1915
|
artikel
|
| 10 |
Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)
|
Chua, Chong Chyn
|
|
|
9 |
8 |
p. 1827-1835
|
artikel
|
| 11 |
Hepatosplenic T-cell lymphoma in children and adolescents
|
Schwartz, Lindsay F.
|
|
|
9 |
8 |
p. 1847-1858
|
artikel
|
| 12 |
Humanizing CAR T-cell therapy in B-ALL
|
Faramand, Rawan
|
|
|
9 |
8 |
p. 1916-1917
|
artikel
|
| 13 |
ICE polychemotherapy is an efficient salvage treatment in primary central nervous system lymphoma: an LOC network study
|
Pérol, Louis
|
|
|
9 |
8 |
p. 1801-1804
|
artikel
|
| 14 |
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial
|
Ragaini, Simone
|
|
|
9 |
8 |
p. 1805-1815
|
artikel
|
| 15 |
Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies
|
Risitano, Antonio M.
|
|
|
9 |
8 |
p. 1816-1826
|
artikel
|
| 16 |
Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia
|
Chow, Ryan D.
|
|
|
9 |
8 |
p. 1888-1899
|
artikel
|
| 17 |
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL
|
Gauthier, Jordan
|
|
|
9 |
8 |
p. 1861-1872
|
artikel
|
| 18 |
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
|
Mehta, Parinda A.
|
|
|
9 |
8 |
p. 1927-1939
|
artikel
|
| 19 |
Platelet spleen tyrosine kinase is a key regulator of anti-PF4 antibody–induced immunothrombosis
|
Zlamal, Jan
|
|
|
9 |
8 |
p. 1772-1785
|
artikel
|
| 20 |
Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial
|
Raiola, Anna Maria
|
|
|
9 |
8 |
p. 1966-1975
|
artikel
|
| 21 |
Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia
|
Okeleji, Olayinka
|
|
|
9 |
8 |
p. 1988-1990
|
artikel
|
| 22 |
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with novel FGFR1 fusion treated with pemigatinib
|
Torres-Cabala, Carlos A.
|
|
|
9 |
8 |
p. 1786-1790
|
artikel
|
| 23 |
Sickle cell care and implementation science
|
Bello-Manga, Halima
|
|
|
9 |
8 |
p. 1859-1860
|
artikel
|
| 24 |
Stroke prevention in Hispanic children with sickle cell anemia: the SACRED trial
|
Nieves, Rosa M.
|
|
|
9 |
8 |
p. 1791-1800
|
artikel
|
| 25 |
Targeting RNA modification and mitochondrial metabolism cross talk in leukemic stem cells with CDK7 inhibitor TGN-1062
|
Kang, Hyunjun
|
|
|
9 |
8 |
p. 1900-1906
|
artikel
|
| 26 |
Targeting the DNA damage response through TBL1X in mantle cell lymphoma
|
Pray, Betsy
|
|
|
9 |
8 |
p. 2006-2018
|
artikel
|
| 27 |
Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma
|
Liu, Jia
|
|
|
9 |
8 |
p. 1991-2005
|
artikel
|
| 28 |
Unraveling antibody-induced structural dynamics in the ADAMTS13 CUB1-2 domains via HDX-MS
|
Bonnez, Quintijn
|
|
|
9 |
8 |
p. 1763-1771
|
artikel
|
Tijdschrift beschrijving